Evidence map›Paper›PMID 31484581›Full record

ArticleMolecular cancer2019

RNA-Seq profiling of circular RNA in human lung adenocarcinoma and squamous cell carcinoma.

Chengdi Wang, Shuangyan Tan, Wen-Rong Liu, Qian Lei, Wenliang Qiao, Yangping Wu, Xiaoqi Liu, Wei Cheng, Yu-Quan Wei, Yong Peng and 1 more

Abstract readLetter
In one paragraph

Article in Molecular cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Circular RNAJournal of thoracic disease · 2024
    Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chengdi WangDepartment of Respiratory and Critical Care Medicine, West China Medical School/West China Hospital, Sichuan University, Chengdu, 610041, China.
Shuangyan TanState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Wen-Rong LiuState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Qian LeiDepartment of Targeted Tracer Research and Development Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, China.
Wenliang QiaoLung Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Yangping WuDepartment of Targeted Tracer Research and Development Laboratory, West China Hospital, Sichuan University, Chengdu, 610041, China.
Xiaoqi LiuState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Wei ChengState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Yu-Quan WeiState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Yong PengState Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, China. yongpeng@scu.edu.cn.ORCID 0000-0002-1181-3467
Weimin LiDepartment of Respiratory and Critical Care Medicine, West China Medical School/West China Hospital, Sichuan University, Chengdu, 610041, China. weimi003@scu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging evidences demonstrate that circular RNAs (circRNAs) are abnormally expressed in tumors and could serve as prognostic markers for cancers. However, the expression patterns and clinical implications of circRNAs in non-small cell lung cancer (NSCLC) remain obscure. In this study, we profiled circRNA expressions in 10 pairs of lung adenocarcinoma (LUAD) and squamous cell carcinoma (LUSC) after ribosomal RNA-depletion and RNase R digestion to enrich circRNAs. Combining five circRNA computational programs, we found that LUAD and LUSC not only share common expression patterns, but also exhibit distinct circRNA expression signatures. Moreover, the Receiver Operating Characteristic (ROC) curve analysis indicated that hsa_circ_0077837 and hsa_circ_0001821 could serve as potential biomarkers for both LUAD and LUSC, while hsa_circ_0001073 and hsa_circ_0001495 could be diagnostic/subtyping marker for LUAD and LUSC, respectively. Therefore, our findings highlight the important diagnostic potential of circRNAs in NSCLC.

Indexed as

Biomarkers, TumorGene Expression ProfilingRNA, CircularAdenocarcinoma of LungCarcinoma, Squamous CellComputational BiologyHumansLung NeoplasmsROC CurveTranscriptomeBiomarkers, TumorRNA, CircularcircRNA sequencingCircular RNAsLung adenocarcinomaLung squamous carcinoma

Identifiers

PMID31484581
PMCPMC6724331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.